$21.380
+1.127 (+5.27%)收盘时
- 最高
- 21.430
- 开盘
- 20.320
- 成交量加权均价
- 21.04
- 成交量
- 70.07K
- 市值
- 548.94M
- 最低
- 20.320
- 成交额
- 1.47M
- 企业价值/息税折旧摊销前利润（TTM）
- 67.50
NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.
AI 分析 of National Research Corp (NRC)
持有Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.
估值指标
事件时间线
资讯
6.510-15NewsfilterStudy on Experience Management in High-Performing Healthcare Organizations
- 9.009-21Newsfilter
Four Considerations to Enhance Hospital Governance
- 7.509-02Newsfilter
NRC Health Partners with Healthcare Leaders to Enhance Patient Experience
8.007-29seekingalphaNational Research Declares Quarterly Dividend of $0.16
- 9.507-29seekingalpha
NRC Health Reports Strong Q2 2026 Earnings with 11% TRCV Growth
NRC 常见问题 —— 由 Alphio AI 解答
NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. It operates in the Industrials sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.
社区
更多 ↗暂无帖子
注册或登录后参与讨论本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。